Back to Dashboard





Amgen Inc. (AMGN)
Real-time intraday values
Market Overview
From:
To:
AMGN Intraday
No data available
SymbolAMGN
IPO DateJun 17, 1983
CEOMr. Robert A. Bradway
Full Time Employees31.5k
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUnited States
ExchangeNasdaqGS
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Performance
| Period | Return % | Value Change |
|---|---|---|
| 1 Day | -0.63% | -2.77 US$ |
| 5 Days | -6.36% | -29.62 US$ |
| 1 Month | -0.52% | -2.29 US$ |
| 6 Months | +28.51% | +96.75 US$ |
Analyzing Market with AI
Evaluating the last 30 days of history and fundamental metrics of AMGN...
Key Statistics
Market Cap
235.64B
P/E Ratio
25.25
Div Yield
2.30%
52W High
$483.99
52W Low
$312.39
Analyst Consensus
ConsensusHold
Bullish1132.4%
Neutral1852.9%
Bearish514.7%
52W Analyst Price Targets
Min Target
$230.00
$230.00
Max Target
$542.00
$542.00
Current$436.05
Avg Target$437.01
Analyst Recommendations
Target Price:$437.01($230.00 - $542.00)
Looking for more stocks? Explore them in the screener
Community Thoughts
Share your analysis and sentiment on AMGN
Join the community to share your analysis
Latest News for AMGN
Mizuho Adjusts Price Target on Amgen to $388 From $352, Maintains Neutral Rating
MT Newswires•Nov 20, 2026, 03:14 PM

Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Zacks•Nov 20, 2026, 01:00 PM
What SPDR Dow Jones Industrial Avg ETF (DIA) Bought: Goldman Leads on Nov. 18
GuruFocus.com•Nov 20, 2026, 11:03 AM
Amgen Inc's Dividend Analysis
GuruFocus.com•Nov 20, 2026, 10:01 AM
Securitize Adds Anthropic to Tokenized Stock Platform
MT Newswires•Nov 19, 2026, 06:25 PM

Viridian Therapeutics initiated at 'buy' by Bank of America with $47 price target
Proactive•Nov 19, 2026, 05:48 PM
Viridian Therapeutics' Lumvoa Emerging as Rival to Amgen's Tepezza, BofA Securities Says
MT Newswires•Nov 19, 2026, 04:02 PM

Eli Lilly Stopped Touting Dose Counts. Should You Worry?
Trefis•Nov 19, 2026, 03:09 PM

Amgen (AMGN) Has Advanced MariTide Into Phase 3 Trials
Simply Wall St.•Nov 19, 2026, 02:19 PM

Should You Buy Exelixis Stock For Its Cash?
Trefis•Nov 19, 2026, 11:43 AM